|
|
Exchange: |
N/A |
Security
Type: |
Common |
Shares
Out: |
68,990,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$0 - $0 |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Bicycle Therapeutics is a holding company. Through its subsidiaries, Co. is a clinical-stage biopharmaceutical company developing a class of medicines, which it refers to as Bicycles. Bicycles are a therapeutic modality combining the pharmacology associated with a biologic with the manufacturing and pharmacokinetic properties of a small molecule. Co. is evaluating BT5528, a Bicycle Toxin Conjugate (BTC) targeting Ephrin type-A receptor 2, BT8009, a BTC targeting Nectin-4, and BT7480, a Bicycle tumor-targeted immune cell agonist® targeting Nectin-4 and agonizing CD137. In addition, BT1718, a BTC that is being developed to target tumors that express Membrane Type 1 matrix metalloproteinase.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
0 |
Total Buy Value |
$0 |
$0 |
$0 |
$0 |
Total People Bought |
0 |
0 |
0 |
0 |
Total Buy Transactions |
0 |
0 |
0 |
0 |
Total Shares Sold |
7,268 |
14,490 |
37,488 |
61,094 |
Total Sell Value |
$142,744 |
$314,362 |
$724,634 |
$1,369,761 |
Total People Sold |
7 |
7 |
7 |
9 |
Total Sell Transactions |
7 |
14 |
26 |
45 |
End Date |
2024-06-27 |
2024-03-26 |
2023-09-26 |
2022-09-26 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Keen Nicholas |
Chief Scientific Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
66,233 |
|
- |
|
Skynner Michael |
Chief Technology Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
28,000 |
98,482 |
|
- |
|
Kender Richard N |
Director |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
16,750 |
|
- |
|
Young Alethia |
Chief Financial Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
12,000 |
12,000 |
|
- |
|
Thompson Travis Alvin |
Chief Accounting Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
16,000 |
23,979 |
|
- |
|
Winter Gregory Paul |
Director |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
6,000 |
180,677 |
|
- |
|
Arroyo Santiago |
Chief Development Officer |
|
2024-01-02 |
4 |
A |
$0.00 |
$0 |
D/D |
17,340 |
17,340 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2023-10-03 |
4 |
S |
$20.00 |
$29,400 |
D/D |
(1,470) |
322,131 |
|
- |
|
Milnes Alistair |
Chief Operating Officer |
|
2023-10-03 |
4 |
S |
$20.00 |
$8,840 |
D/D |
(442) |
36,839 |
|
- |
|
Skynner Michael |
Chief Technology Officer |
|
2023-10-03 |
4 |
S |
$20.00 |
$8,840 |
D/D |
(442) |
70,482 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2023-10-03 |
4 |
S |
$20.00 |
$8,840 |
D/D |
(442) |
29,359 |
|
- |
|
Keen Nicholas |
Chief Scientific Officer |
|
2023-10-03 |
4 |
S |
$20.00 |
$5,440 |
D/D |
(272) |
38,233 |
|
- |
|
Thompson Travis Alvin |
Chief Accounting Officer |
|
2023-10-03 |
4 |
S |
$20.00 |
$1,080 |
D/D |
(54) |
7,979 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2023-07-03 |
4 |
S |
$25.10 |
$11,320 |
D/D |
(451) |
29,801 |
|
- |
|
Keen Nicholas |
Chief Scientific Officer |
|
2023-07-03 |
4 |
S |
$25.10 |
$8,434 |
D/D |
(336) |
38,505 |
|
- |
|
Skynner Michael |
Chief Technology Officer |
|
2023-07-03 |
4 |
S |
$25.10 |
$11,320 |
D/D |
(451) |
70,924 |
|
- |
|
Thompson Travis Alvin |
Chief Accounting Officer |
|
2023-07-03 |
4 |
S |
$25.10 |
$1,531 |
D/D |
(61) |
8,033 |
|
- |
|
Milnes Alistair |
Chief Operating Officer |
|
2023-07-03 |
4 |
S |
$25.10 |
$11,320 |
D/D |
(451) |
37,281 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2023-07-03 |
4 |
S |
$25.10 |
$37,600 |
D/D |
(1,498) |
323,601 |
|
- |
|
Thompson Travis Alvin |
Chief Accounting OfficerOffice |
|
2023-06-22 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
8,094 |
|
- |
|
Crockett Nigel |
Chief Business Officer |
|
2023-04-03 |
4 |
S |
$21.11 |
$9,436 |
D/D |
(447) |
30,252 |
|
- |
|
Skynner Michael |
Chief Technology Officer |
|
2023-04-03 |
4 |
S |
$21.11 |
$9,436 |
D/D |
(447) |
71,375 |
|
- |
|
Lee Kevin |
Chief Executive Officer |
|
2023-04-03 |
4 |
S |
$21.11 |
$31,369 |
D/D |
(1,486) |
325,099 |
|
- |
|
Kalowski Lee |
President and CFO |
|
2023-04-03 |
4 |
S |
$21.11 |
$7,937 |
D/D |
(376) |
30,309 |
|
- |
|
Keen Nicholas |
Chief Scientific Officer |
|
2023-04-03 |
4 |
S |
$21.11 |
$6,734 |
D/D |
(319) |
38,841 |
|
- |
|
226 Records found
|
|
Page 2 of 10 |
|
|